Brief: Liminal Biosciences Says Cash And Cash Equivalents On March 31 Was $21.6 Mln

Liminal BioSciences

17/05/2021 22:17

May 17 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES REPORTS FIRST QUARTER 2021 FINANCIAL
RESULTS
    * LIMINAL BIOSCIENCES INC - CASH AND CASH EQUIVALENTS AT
MARCH 31,
2021 WERE $21.6 MILLION
    * LIMINAL BIOSCIENCES INC - NET LOSS WAS $20.9 MILLION FOR
Q1 OF
2021 COMPARED TO $27.7 MILLION FOR Q1 OF 2020
    * LIMINAL BIOSCIENCES INC - CURRENT EXPECTED PDUFA TARGET
ACTION
DATE FOR RYPLAZIM IS JUNE 5, 2021

Source text for Eikon:  ID:nCNWNd4kxa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))